Back
Grants Ex Parte Injunction To GlaxoSmithKline Against Orion Biotech For
In a significant move to protect intellectual property rights, the has issued an against and other associated entities. The order restrains the defendants from using the trademark 'COBEX' in connection with their medicinal products, following a lawsuit filed by .
Case Background
The dispute arises from the alleged infringement of GSK’s long-standing trademark, 'COBADEX'. GSK, a global pharmaceutical leader, has been manufacturing and marketing its multi-vitamin formulation under the 'COBADEX' brand since , with trademark rights dating back to .
The plaintiff approached the Court seeking a , , and of products, alleging that the defendants’ use of the mark 'COBEX' for a paediatric antibiotic is not only but also poses a substantial risk to consumers due to the potential for confusion between the two distinct drug formulations.
Arguments and Legal Analysis
During the proceedings, counsel for the plaintiff emphasized that the defendants had applied for registration of the 'COBEX' mark in , claiming usage since . However, GSK contended that the high degree of similarity between the marks creates an imminent risk of confusion. The Court was informed that the confusion could have severe health implications, as the products are intended for different therapeutic purposes—one being a multi-vitamin and the other a paediatric antibiotic.
The Court, presided over by Hon'ble Mr. Justice Anup Jairam Bhambhani, examined the preliminary facts and cited established legal principles. By relying on the ruling in and the Division Bench decision in , the Court allowed the plaintiff to bypass requirements given the urgent nature of the matter.
Key Observations
The bench highlighted the urgency of the matter, noting that the likelihood of consumer confusion in the pharmaceutical industry necessitates judicial intervention:
-
"In the opinion of this court, the plaintiff has made-out a case in its favour and against the defendants."
-
"Furthermore, considering the facts obtaining in the matter, the also lies in favour of the plaintiff and would result to the plaintiff if the sought is not granted."
-
"Counsel submits therefore, that not only is there imminent chance of confusion between the plaintiff’s drug ‘COBADEX’ and the defendants’ preparation ‘COBEX’ on account of similarity of the two trade marks, but the fact that one is a multi-vitamin and the other is an antibiotic meant for paediatric use, heightens the risk to the consumer."
Court’s Decision
Justice Bhambhani granted an , restraining the defendants from manufacturing, selling, advertising, or dealing in products under the 'COBEX' mark or any other name. Additionally, the Court ordered the defendants to remove product listings from all digital platforms, including e-pharmacy websites and social media. The matter is currently slated for further proceedings before the Joint Registrar on . This order marks a critical victory for GSK, reinforcing the protection of established pharmaceutical brands in India.
